Abstract
W Busse, R Buhl, Vidaurre C Fernandez. J Allergy Clin Immunol. 2012;129(4):983–989 Omalizumab, a humanized anti-IgE monoclonal antibody, is an approved treatment for severe persistent asthma in patients 12 years or older. Previous pooled data showed an increased number of malignancies in treated patients compared to control subjects (0.5% vs 0.2%, respectively). This study reexamined the malignancy risk from the use of omalizumab. Sixty-seven phase I to IV clinical trials sponsored by the medication’s manufacturers and their extension periods were pooled for analysis. Studies were categorized as randomized, double-blind, placebo-controlled (RDBPC, 32/67), controlled …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
